Clearside Biomedical, Inc. (NASDAQ:CLSD) Files An 8-K Regulation FD Disclosure

Item7.01

On February27, 2017, Clearside Biomedical, Inc. (the Registrant)
issued a press release announcing the redirection of its
resources from its wet age-related macular degeneration (wet AMD)
research to its diabetic macular edema (DME) clinical development
program, as described below.

A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K. The information set forth in this
Item7.01 and contained in the press release furnished as Exhibit
99.1 shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
and is not incorporated by reference into any of the Registrants
filings under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof,
except as shall be expressly set forth by specific reference in
any such filing.

In the press release described above, the Registrant announced
that it has initiated a strategic realignment of its research
resources from its pre-clinical development program for axitinib
for the treatment of wet AMD toward its ongoing clinical
development program for Zuprata, its proprietary suspension
formulation of the corticosteroid triamcinolone acetonide,
together with an anti-VEGF agent, for the treatment of DME. While
the Registrant plans to continue to investigate axitinib and
other compounds for the treatment of wet AMD, it no longer
expects to submit an Investigational New Drug application to the
U.S. Food and Drug Administration.

(d)Exhibits

2

About Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Recent Trading Information

Clearside Biomedical, Inc. (NASDAQ:CLSD) closed its last trading session up +0.35 at 8.41 with 542,889 shares trading hands.